MSD
MK6482 + lenvatinib / cabozantinib
Biodrugs/ Drugs
Cancer
MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy.
3Phase III in Spain,
2Phase II,
1Phase I